Biotech's wellspring: the health of private biotech in 2013

An Erratum to this article was published on 09 June 2014

This article has been updated

The biotech boom in public markets is trickling down and reinvigorating the US private sector, but European startup funding continues to stagnate.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

14 May 2014
In the version of this article initially published, in Box 3, it was reported that “Catabasis will instead monitor the situation as it approaches phase 3, when large amounts of capital will be required....” The line should have read, “Catabasis instead is keeping with its plan to develop the phase 2 package for its lead program and timing a public financing with phase 3 trials....” Michael Jirousek was also incorrectly identified as founder and CEO. He is the company's co-founder and CSO. On p. 431, column 2, Adam Cutler was incorrectly quoted as saying, “...but today, anyone “deemed to have an exciting enough technology platform with big enough names involved, either in management or on the board or as scientific founders—that's enough to get people excited.” It should have read, “...but in 2013 and the beginning of 2014, anyone “deemed to have an exciting enough technology platform with big enough names involved, either in management or on the board or as scientific founders—that was enough to get people excited.”

Authors

Brady Huggett
View author publications
You can also search for this author in PubMed Google Scholar

Huggett, B. Biotech's wellspring: the health of private biotech in 2013. Nat Biotechnol 32, 428–435 (2014). https://doi.org/10.1038/nbt.2905